Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Kedudukan dalam Saham #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Harga Saham
$41.14
Disegerakkan terakhir: 2026-09-21
Modal Pasaran
$182.76B
Perubahan (1 hari)
-7.78%
Perubahan (1 tahun)
-32.24%
Negara
DK
Perdagangan Novo Nordisk A/S (NOVO-B)

Kategori

Hasil untuk Novo Nordisk A/S (NOVO-B)
Hasil pada Jun 2026 TTM: $52.30B
Menurut laporan kewangan terkini daripada Novo Nordisk A/S, hasil semasa syarikat (TTM) ialah $52.30B. Pada tahun 2024, syarikat memperoleh hasil sebanyak $40.52B peningkatan berbanding hasil pada tahun 2023 iaitu $34.39B. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Novo Nordisk A/S dari 2000 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $52.30B 12.04%
2025 $46.68B 15.22%
2024 $40.52B 17.82%
2023 $34.39B 35.02%
2022 $25.47B 18.29%
2021 $21.53B 3.33%
2020 $20.84B 13.79%
2019 $18.31B 6.63%
2018 $17.17B -4.59%
2017 $18.00B 13.46%
2016 $15.86B 0.88%
2015 $15.73B 8.89%
2014 $14.44B -6.28%
2013 $15.41B 11.69%
2012 $13.80B 19.42%
2011 $11.55B 6.01%
2010 $10.90B 10.52%
2009 $9.86B 15.53%
2008 $8.54B 3.65%
2007 $8.24B 20.44%
2006 $6.84B 28.15%
2005 $5.34B -0.14%
2004 $5.34B 18.51%
2003 $4.51B 27.01%
2002 $3.55B 25.45%
2001 $2.83B 9.05%
2000 $2.60B 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$79.67B 52.31%
US
$97.93B 87.23%
US
$64.39B 23.10%
US
$77.52B 48.21%
CH
$66.40B 26.95%
US